Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report
Pierre-Olivier Gaudreau, J. Jack Lee, John V. Heymach, Don L. Gibbons
Topics & Concepts
DurvalumabMedicineTremelimumabSelumetinibnon-small cell lung cancer (NSCLC)NivolumabImmunotherapyOncologyInternal medicineAtezolizumabMEK inhibitorLung cancerMAPK/ERK pathwayCancerKinaseIpilimumabBiologyKRASA549 cellColorectal cancerCell biologyCancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsColorectal Cancer Treatments and Studies